Technical Analysis for ASND - Ascendis Pharma A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Historical ASND trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 5.99% | |
| Slingshot Bearish | Bearish Swing Setup | 5.91% | |
| MACD Bullish Signal Line Cross | Bullish | 5.91% | |
| Oversold Stochastic | Weakness | 5.91% | |
| New 52 Week Closing Low | Bearish | 8.88% | |
| Lizard Bullish | Bullish Day Trade Setup | 8.88% | |
| NR7 | Range Contraction | 8.88% | |
| Doji - Bullish? | Reversal | 8.88% | |
| New 52 Week Low | Weakness | 8.88% | |
| Multiple of Ten Bullish | Other | 8.88% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 3 hours ago |
| Rose Above Upper Bollinger Band | about 3 hours ago |
| 10 DMA Support | about 3 hours ago |
| Up 5% | about 3 hours ago |
| Up 3% | about 4 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 03/10/2021
Ascendis Pharma A/S Description
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Pulmonary Arterial Hypertension Breakthrough Therapy Peptide Hormones Growth Hormone Treatment Of Diabetes Drug Therapies Recombinant Proteins Growth Hormone Deficiency Growth Hormone Therapy Prodrug Treprostinil United Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 183.98 |
| 52 Week Low | 119.29 |
| Average Volume | 221,812 |
| 200-Day Moving Average | 151.84 |
| 50-Day Moving Average | 141.35 |
| 20-Day Moving Average | 127.16 |
| 10-Day Moving Average | 124.53 |
| Average True Range | 4.83 |
| ADX | 37.33 |
| +DI | 14.40 |
| -DI | 26.14 |
| Chandelier Exit (Long, 3 ATRs ) | 131.07 |
| Chandelier Exit (Short, 3 ATRs ) | 133.78 |
| Upper Bollinger Band | 133.80 |
| Lower Bollinger Band | 120.52 |
| Percent B (%b) | 0.33 |
| BandWidth | 10.44 |
| MACD Line | -5.07 |
| MACD Signal Line | -5.52 |
| MACD Histogram | 0.4504 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 128.75 | ||||
| Resistance 3 (R3) | 128.55 | 127.08 | 128.12 | ||
| Resistance 2 (R2) | 127.08 | 126.11 | 127.18 | 127.90 | |
| Resistance 1 (R1) | 126.01 | 125.51 | 126.55 | 126.21 | 127.69 |
| Pivot Point | 124.54 | 124.54 | 124.81 | 124.64 | 124.54 |
| Support 1 (S1) | 123.47 | 123.57 | 124.01 | 123.67 | 122.19 |
| Support 2 (S2) | 122.00 | 122.97 | 122.10 | 121.98 | |
| Support 3 (S3) | 120.93 | 122.00 | 121.77 | ||
| Support 4 (S4) | 121.13 |
